Results 11 to 20 of about 68,603 (270)

The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab. [PDF]

Cancers (Basel), 2023
Kuźniewska A, Majeranowski A, Henry S, Kowalska D, Stasiłojć G, Urban A, Zaucha JM, Okrój M.   +7 more
europepmc   +3 more sources

Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification. [PDF]

Front Immunol
Majeranowski A, Stasiłojć G, Panasiuk N, Okrój M.   +3 more
europepmc   +3 more sources

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement-dependent cytotoxicity. [PDF]

FEBS J
Pinto AJ, Chouquet A, Bally I, Rossi V, Thielens NM, Dumestre-Pérard C, Kunert R, Gaboriaud C, Ling WL, Reiser JB.   +9 more
europepmc   +2 more sources

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells. [PDF]

Sci Rep
Pape LJ, Gebhardt AJ, Dannenberg M, Risch H, Duttmann A, Weisel K, Hambach J, Koch-Nolte F, Bannas P.   +8 more
europepmc   +3 more sources

Jo-1 Antibodies From Myositis Induce Complement-Dependent Cytotoxicity and TREM-1 Upregulation in Muscle Endothelial Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2023
Honda M, Shimizu F, Sato R, Mizukami Y, Watanabe K, Takeshita Y, Maeda T, Koga M, Kanda T.   +8 more
europepmc   +3 more sources

P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB [PDF]

Hemasphere, 2023
Hiemstra I, Santegoets K, Janmaat M, Ten Hagen W, Sanchez R, Brady L, Bosgra S, Overdijk M, Chen J, Fladeland Iversen K, Plesner T, Breij E.   +11 more
europepmc   +2 more sources

The Anti-Human P2X7 Monoclonal Antibody (Clone L4) Can Mediate Complement-Dependent Cytotoxicity of Human Leukocytes. [PDF]

Eur J Immunol
Elhage A, Watson D, Sluyter R.
europepmc   +3 more sources

Claudin-2 enhances human antibody-mediated complement-dependent cytotoxicity of porcine endothelial cells by modulating antibody binding and complement activation. [PDF]

Front Immunol
Li W, Yang F, Yang D, Song Z, Xu Z, Wu J, Li Y, Chen Z, Chen P, Yu Y, Xie T, Yang C, Zhou L, Luan S, Gao H.   +14 more
europepmc   +3 more sources

Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay. [PDF]

Sci Rep
Schmidt S, Geisel A, Enzlein T, Fröhlich BC, Pritchett L, Verneret M, Graf C, Hopf C.   +7 more
europepmc   +2 more sources

Anti-HER2 Cancer-Specific mAb, H₂Mab-250-hG₁, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. [PDF]

Int J Mol Sci
Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y.   +4 more
europepmc   +2 more sources